NEW YORK (GenomeWeb News) – Quest Diagnostics today reported that second-quarter revenues were essentially flat compared to a year ago.

For the three months ended June 30, revenues inched up .5 percent year over year to $1.91 billion, up from $1.90 billion, missing Wall Street estimates of $1.94 billion.

Clinical testing revenues during the quarter inched up .7 percent, Quest said.

SG&A spending was down 5 percent to $440.8 million from $462.8 million a year ago.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: oral microbiomes of dogs and their owners, Plasmodium vivax population structure, and more.

The American Society of Human Genetics has issued a position statement on genetic testing of children.

The White House seeks to update how biotechnology products are regulated.

Team science leads some researchers to get lost in the shuffle, the Chronicle of Higher Education reports.